1272 related articles for article (PubMed ID: 9502296)
1. Facilitation of parental-strain marrow engraftment by T cells of neonatally-tolerant mice.
Davenport C; George T; Devora GA; Morris MA; Gordon BE; Kumar V; Bennett M
Biol Blood Marrow Transplant; 1997 Dec; 3(6):294-303. PubMed ID: 9502296
[TBL] [Abstract][Full Text] [Related]
2. Rapid rejection of H2k and H2k/b bone marrow cell grafts by CD8+ T cells and NK cells in irradiated mice.
Davenport C; Kumar V; Bennett M
J Immunol; 1995 Oct; 155(8):3742-9. PubMed ID: 7561078
[TBL] [Abstract][Full Text] [Related]
3. Use of newborn liver cells as a murine model for cord blood cell transplantation.
Davenport C; Kumar V; Bennett M
J Immunol; 1993 Aug; 151(3):1597-605. PubMed ID: 8101544
[TBL] [Abstract][Full Text] [Related]
4. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
5. The effects of polyinosinic:polycytidylic acid (pI:C) on the graft-vs-host (GVH) reaction. II. Increased NK-mediated rejection on C57BL/6 lymphocytes by (C57BL/6 X A)F1 mice.
Peres A; Nestel FP; Seemayer TA; Lapp WS
J Immunol; 1986 Dec; 137(11):3420-7. PubMed ID: 3537120
[TBL] [Abstract][Full Text] [Related]
6. An absence of T cells in murine bone marrow allografts leads to an increased susceptibility to rejection by natural killer cells and T cells.
Murphy WJ; Kumar V; Cope JC; Bennett M
J Immunol; 1990 May; 144(9):3305-11. PubMed ID: 2329274
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
8. Leucyl-leucine methyl ester treatment of donor cells permits establishment of immunocompetent parent----F1 chimeras that are selectively tolerant of host alloantigens.
Thiele DL; Calomeni JA; Lipsky PE
J Immunol; 1987 Oct; 139(7):2137-42. PubMed ID: 3309052
[TBL] [Abstract][Full Text] [Related]
9. Studies of immunologic tolerance to host minor histocompatibility antigens following allogeneic bone marrow transplantation in mice.
Perreault C; Allard A; Brochu S; Poupart C; Fontaine P; Bélanger R; Gyger M
Bone Marrow Transplant; 1990 Aug; 6(2):127-35. PubMed ID: 2145050
[TBL] [Abstract][Full Text] [Related]
10. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).
Ildstad ST; Wren SM; Bluestone JA; Barbieri SA; Stephany D; Sachs DH
J Immunol; 1986 Jan; 136(1):28-33. PubMed ID: 2933464
[TBL] [Abstract][Full Text] [Related]
11. Donor-type activated natural killer cells promote marrow engraftment and B cell development during allogeneic bone marrow transplantation.
Murphy WJ; Bennett M; Kumar V; Longo DL
J Immunol; 1992 May; 148(9):2953-60. PubMed ID: 1573278
[TBL] [Abstract][Full Text] [Related]
12. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S
Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
[TBL] [Abstract][Full Text] [Related]
13. Donor double-negative Treg promote allogeneic mixed chimerism and tolerance.
He KM; Ma Y; Wang S; Min WP; Zhong R; Jevnikar A; Zhang ZX
Eur J Immunol; 2007 Dec; 37(12):3455-66. PubMed ID: 18000953
[TBL] [Abstract][Full Text] [Related]
14. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
15. Anti-NK cell treatment induces stable mixed chimerism in MHC-mismatched, T cell-depleted, nonmyeloablative bone marrow transplantation.
Cho SG; Shuto Y; Soda Y; Nakazaki Y; Izawa K; Uchimaru K; Takahashi S; Tani K; Tojo A; Asano S
Exp Hematol; 2004 Dec; 32(12):1246-54. PubMed ID: 15588949
[TBL] [Abstract][Full Text] [Related]
16. Effect of graft-versus-host disease on anti-tumor immunity.
Schreiber KL; Forman J
J Immunol; 1990 Mar; 144(5):2018-26. PubMed ID: 1968493
[TBL] [Abstract][Full Text] [Related]
17. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
Cohen P; Vourka-Karussis U; Weiss L; Slavin S
J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438
[TBL] [Abstract][Full Text] [Related]
18. Lethal graft-vs-host disease across major histocompatibility barriers: requirement for leucyl-leucine methyl ester sensitive cytotoxic T cells.
Thiele DL; Charley MR; Calomeni JA; Lipsky PE
J Immunol; 1987 Jan; 138(1):51-7. PubMed ID: 2946780
[TBL] [Abstract][Full Text] [Related]
19. Co-stimulated/Tc2 cells abrogate murine marrow graft rejection.
Erdmann AA; Jung U; Foley JE; Toda Y; Fowler DH
Biol Blood Marrow Transplant; 2004 Sep; 10(9):604-13. PubMed ID: 15319772
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of natural killer cell-mediated bone marrow graft rejection by allogeneic major histocompatibility complex class I, but not class II molecules.
Ohlén C; Höglund P; Sentman CL; Carbone E; Ljunggren HG; Koller B; Kärre K
Eur J Immunol; 1995 May; 25(5):1286-91. PubMed ID: 7774631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]